Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

EVGN vs CGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

CGEN Overall Winner 6-Pillar Tally: EVGN 1 – 5 CGEN Matrix Metrics: EVGN 0 – 10 CGEN

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 41.2/100 (SELL) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin).

  • Technical & Structure Timing Caution: EVGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.4); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EVGN vs CGEN
EVGN NASDAQ
Evogene Ltd.
Agricultural Chemicals
$0.34
-13.17% 1D
Market Cap $6.0M
TTM Revenue $1.7M
Forward P/E N/M
Beta / 30D Vol 1.37β · 138% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 25.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $0.36 · SMA50: $0.40
CGEN NASDAQ Head-to-Head Winner
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
TTM Revenue $76M
Forward P/E 12.4x
Beta / 30D Vol 1.44β · 62% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $2.02 · SMA50: $2.18

6-Pillar Scorecard Institutional Category Breakdown (EVGN 1 – 5 CGEN)

Columns: Metric · EVGN · CGEN
1. Valuation Multiples CGEN
Forward P/E N/M 12.4x
Trailing P/E N/M 5.2x
PEG Ratio N/M 1.29x
EV / Revenue N/M 2.5x
2. Growth & Scale CGEN
Revenue Growth (YoY) -60.7% +102.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.7M $76M
Market Cap $6.0M $193.2M
3. Profitability & Quality CGEN
Gross Margin -67.6% 86.2%
Operating Margin -858.2% 41.3%
Net Profit Margin 0.0% 47.9%
Return on Equity (ROE) -182.8% 57.2%
4. Balance Sheet & Cash Flow CGEN
Cash Generation (TTM) -$11M $32M EBITDA
Cash Flow Margin N/A 41.9% EBITDA Mgn
Net Cash / Leverage $6.5M Net Cash $4.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVGN
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 89.7% (57th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CGEN
OpEx & R&D Intensity N/A 44.9% of Rev ($34M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EVGN (0) vs CGEN (10)
Institutional Metric EVGN CGEN Criterion Row Edge
Market Capitalization
Scale
$6.0M $193.2M Larger Scale CGEN
Trailing P/E Ratio
Valuation
N/M 5.2x Lower Multiple CGEN
Forward P/E Ratio
Valuation
N/M 12.4x Lower Multiple CGEN
Revenue Growth (YoY)
Growth
-60.7% +102.1% Higher Growth CGEN
Operating Margin (TTM)
Profitability
-858.2% 41.3% Higher Margin CGEN
Net Profit Margin
Profitability
0.0% 47.9% Higher Margin CGEN
Return on Equity (ROE)
Capital Efficiency
-182.8% 57.2% Higher ROE CGEN
52-Week Range Position
Momentum
9% ($0–$1) 33% ($1–$3) Stronger Trend CGEN
Beta / 30D Volatility
Risk Regime
1.37β · 138% Vol 1.44β · 62% Vol Lower Realized Risk CGEN
Unified Institutional Score
Composite Signal
41.2 / 100 (SELL) 47.1 / 100 (HOLD) Higher Composite CGEN
Trailing 12M Revenue (USD)
Operating Scale
$1.7M $76M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-67.6% 86.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.29x PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M ($6.5M Net Cash) $32M EBITDA ($4.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGEN +10.12 pp
EVGN: -7.58% · CGEN: +2.54%
3M Horizon CGEN +26.19 pp
EVGN: -43.4% · CGEN: -17.21%
6M Horizon CGEN +28.28 pp
EVGN: -54.29% · CGEN: -26.01%
1Y Horizon CGEN +95.06 pp
EVGN: -71.89% · CGEN: +23.17%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period EVGN Revenue CGEN Revenue EVGN Op. Margin CGEN Op. Margin Margin Leader
Q3 '25 $0M $10M -873.1% -417.4% CGEN
Q4 '25 $0M $270M -1659.9% 83.2% CGEN
Q1 '26 $0M $10M -943.1% -414.4% CGEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EVGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EVGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase · OBV NEUTRAL
Current IV 89.7%
IV Percentile 57th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EVGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.0M market capitalization and -858.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $193.2M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 44.9% of Rev ($34M)
90D Engineering Disclosures 0 Published

Investor FAQ EVGN vs CGEN Key Questions & Quantitative Answers

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 41.2/100 (SELL) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin). Technical & Structure Timing Caution: EVGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.4); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGEN leads the Growth & Scale pillar: EVGN posts -60.7% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (-67.6% gross margin, -858.2% operating margin), compared with CGEN at +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin). Across the 3-period historical trajectory (Q3 '25 to Q1 '26), EVGN cumulative revenue shifted N/A while CGEN shifted +0.0%. In operating R&D and SG&A reinvestment, EVGN deploys N/A (0 90-day corporate R&D disclosures) versus 44.9% of Rev ($34M) (0 disclosures) for CGEN.

CGEN screens cheaper on headline valuation multiples. EVGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVGN (-182.8% ROE) versus CGEN (57.2% ROE) capital efficiency.

In options market volatility and institutional positioning, EVGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 138% Vol realized risk). By comparison, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.